These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31175103)

  • 21. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
    Gobbi L; Scaparrotta G; Rigato M; Cattarin L; Qassim L; Carraro G; Rossi B; Calò LA
    Ther Apher Dial; 2020 Dec; 24(6):642-647. PubMed ID: 32154642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anemia during pregnancy and in the postpartum: intravenous iron therapy revisited.
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123 Suppl 2():S1-35. PubMed ID: 16360535
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
    Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
    Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
    Papadopoulos M; Patel D; Korologou-Linden R; Goto E; Soondrum K; Fell JME; Epstein J
    Br J Clin Pharmacol; 2018 Apr; 84(4):694-699. PubMed ID: 29266387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
    Tagboto S; Cropper L; Turner J; Pugh-Clarke K
    J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Administration of Intravenous Iron Formulations Induces Complement Activation
    Faria B; Gaya da Costa M; Poppelaars F; Franssen CFM; Pestana M; Berger SP; Daha MR; Gaillard CAJM; Seelen MA
    Front Immunol; 2019; 10():1885. PubMed ID: 31497011
    [No Abstract]   [Full Text] [Related]  

  • 32. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IBD: Intravenous iron in IBD--what's the best preparation?
    Gomollón F; Gisbert JP
    Nat Rev Gastroenterol Hepatol; 2011 Jul; 8(9):477-8. PubMed ID: 21788975
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral or intravenous iron for anemia correction in chronic kidney disease?
    Drüeke TB; Massy ZA
    Kidney Int; 2015 Oct; 88(4):673-5. PubMed ID: 26422625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
    Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
    Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferric carboxymaltose approved for iron deficiency anemia.
    Thompson CA
    Am J Health Syst Pharm; 2013 Sep; 70(17):1458. PubMed ID: 23943169
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of iron supplementation during epoietin treatment for cancer-related anemia.
    Hedenus M; Birgegård G
    Med Oncol; 2009; 26(1):105-15. PubMed ID: 18473194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.